RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
…
Rockwood Research

Corporate filings · Event Monitor · Free for all

← Back

EXELIXIS, INC.

EXEL

Biological Products, (No Diagnostic Substances) · SIC 2836 · CIK 0000939767

SHARE:XLINKEDINEMAIL
Revenue FY2026
$2.32B
Net Income
$0.78B
EPS (Basic)
$2.88
Net Margin
33.7%
ROE
36.2%
Total Equity
$2.16B
Shares Out
248M

EXELIXIS, INC. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2009–FY2026; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Revenue & Net Income (10Y)

Margin Trends

Investor Ownership · 6 funds in our universe

FundPosition Value% of AUMQoQ ChgWeight
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management
$485.8M
1.6%
+4.5%
Renaissance Technologies
Renaissance Technologies
$730.6M
0.8%
(2.2%)
Motley Fool Asset Management
Motley Fool Asset Management
$0.5M
0.0%
(6.7%)
Bridgewater Associates
Bridgewater Associates
$21.8M
0.0%
(16.7%)
Alps Advisors
Alps Advisors
$0.7M
0.0%
+1.3%
First Eagle Investment Management
First Eagle
$0.5M
0.0%
—

Insider Transactions

Reading stored insider transactions…